NCT03935204View on ClinicalTrials.gov

Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

PHASE2CompletedINTERVENTIONAL
Enrollment

627

Participants

Timeline

Start Date

May 13, 2019

Primary Completion Date

October 18, 2019

Study Completion Date

April 1, 2021

Conditions
Condylomata AcuminataCervical Cancer
Interventions
BIOLOGICAL

HPV Vaccine,270μg/1.0ml

HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

BIOLOGICAL

Placebo

Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

Trial Locations (1)

210009

Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing

All Listed Sponsors
collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

collaborator

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

INDUSTRY

lead

Xiamen University

OTHER

NCT03935204 - Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | Biotech Hunter | Biotech Hunter